1. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Issue 10349 (30th July 2022) Authors: Abani, Obbina; Abbas, Ali; Abbas, Fatima; Abbas, Joshua; Abbas, Kasim; Abbas, Mustafa; Abbasi, Sadia; Abbass, Hakam; Abbott, Alfie; Abbott, Alison; Abdallah, Nabeel; Abdelaziz, Ammar; Abdelaziz, Ashraf; Abdelfattah, Mohamed; Abdelqader, Bushra; Abdul, Audrey; Abdul, Basir; Abdul, Siddiqui; Abdul ... Journal: Lancet Issue: Volume 400:Issue 10349(2022) Page Start: 359 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis. (April 2023) Authors: Martin, Christopher A.; Nazareth, Joshua; Jarkhi, Amar; Pan, Daniel; Das, Mrinal; Logan, Nicola; Scott, Sam; Bryant, Luke; Abeywickrama, Neha; Adeoye, Oluwatobi; Ahmed, Aleem; Asif, Aqua; Bandi, Srini; George, Nisha; Gohar, Marjan; Gray, Laura J.; Kaszuba, Ross; Mangwani, Jitendra; Martin, Marian... Journal: EClinicalMedicine Issue: Volume 58(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Issue 10387 (6th May 2023) Authors: Abani, Obbina; Abbas, Ali; Abbas, Fatima; Abbas, Joshua; Abbas, Kasim; Abbas, Mustafa; Abbasi, Sadia; Abbass, Hakam; Abbott, Alfie; Abbott, Alison; Abdallah, Nabeel; Abdelaziz, Ammar; Abdelaziz, Ashraf; Abdelfattah, Mohamed; Abdelqader, Bushra; Abdul, Audrey; Abdul, Basir; Abdul, Siddiqui; Abdul ... Journal: Lancet Issue: Volume 401:Issue 10387(2023) Page Start: 1499 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Issue 8 (August 2022) Authors: Munro, Alasdair P S; Feng, Shuo; Janani, Leila; Cornelius, Victoria; Aley, Parvinder K; Babbage, Gavin; Baxter, David; Bula, Marcin; Cathie, Katrina; Chatterjee, Krishna; Dodd, Kate; Enever, Yvanne; Qureshi, Ehsaan; Goodman, Anna L; Green, Christopher A; Harndahl, Linda; Haughney, John; Hicks, Al... Journal: Lancet infectious diseases Issue: Volume 22:Issue 8(2022) Page Start: 1131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗